Table 2. Cox proportional hazard model for factors associated with all-cause mortality in patients whose baseline serum 4COL7S ≥ 6.1 ng/mL (N = 163 with nine censored events).
| Variables | P (uni) | Hazard ratio (95% CI) | P (multi) |
|---|---|---|---|
| Age > 60 years | 0.62 | 1.25 (0.22–7.21) | 0.80 |
| Sex, male | 0.73 | 2.13 (0.45–10.1) | 0.34 |
| Prior history of HCC, yes | 0.45 | 1.29 (0.41–12.5) | 0.73 |
| Platelet count < 10 × 104/μL, pre-treatment | 0.0271* | 6.62 (1.19–36.9) | 0.0308* |
| Serum albumin < 3.5 g/dL, at SVR12 | 0.12 | 5.31 (0.88–31.8) | 0.07 |
| eGFR < 60 mL/min/1.73m2, at SVR12 | 0.49 | 2.27 (0.41–12.5) | 0.35 |
| 4COL7S-defined fibrosis ProgressionSVR† | 0.0141* | 9.12 (2.34–35.4) | 0.0051** |
Factors that are statistically not significant by univariate analyses: pre-treatment FIB-4 index (P = 0.92), APRI (P = 0.62), and Forns index (P = 0.19).
† 4COL7S-defined fibrosis progressionSVR: a change rate of serum 4COL7S from pre-treatment to SVR12 ≥ 0% is defined as fibrosis progressionSVR.
Abbreviations: 4COL7S, type IV collagen 7S fragment; uni, univariate; HCC, hepatocellular carcinoma; SVR, sustained virological response; eGFR, estimated glomerular filtration rate